International Journal of Immunology

Volume 9, Issue 3, September 2021

  • The Regulatory Effect of ERK1 Pathway in the DNA Hypomethylation of MRL/lpr Mice

    Miaoxuan Luo, Shanshan Wei, Xiangbin Mi, Tangde Zhang, Wu Zhang

    Issue: Volume 9, Issue 3, September 2021
    Pages: 41-46
    Received: Jul. 17, 2021
    Accepted: Aug. 09, 2021
    Published: Aug. 18, 2021
    Downloads:
    Views:
    Abstract: Background: Defective ERK1 activity may regulate the DNA hypomethylation in T cells of lupus mice. Aims: To investigate the function of ERK1 in regulating DNA hypomethylation and explore the potential molecular mechanisms involved in lupus mice. Methods: CD4+T cells were isolated from MRL/lpr and BALB/c mice, activated in vitro in the presence or a... Show More
  • Immunohistochemical Expression of MMP-2 in Pancreatic Carcinoma and Chronic Pancreatitis

    Afaf Taha El-Nashar, Eman Muhammad Salah Muhammad, Mohammed Hamdy Sayed, Said Abuel-kheer Mohammed

    Issue: Volume 9, Issue 3, September 2021
    Pages: 47-53
    Received: Mar. 06, 2021
    Accepted: Mar. 16, 2021
    Published: Aug. 19, 2021
    Downloads:
    Views:
    Abstract: Introduction: Matrix metalloproteinase (MMP)-2 is a member of MMPs family which is zinc-dependent endopeptidases that degrade all components of ECM and vascular basement membrane. MMPs are closely involved in tumor invasion and metastasis. Aim of the work: is to evaluate the immune-expression and clinical significance of MMPs molecule in patients w... Show More
  • A Case of Recurrence/Refractory Mediastinal Hodgkin's Lymphoma Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation: Immunotherapy Brings Hope

    Jiaxin Wang, Jiaxiong Tan, Yuhong Lu

    Issue: Volume 9, Issue 3, September 2021
    Pages: 54-58
    Received: Sep. 03, 2021
    Accepted: Sep. 17, 2021
    Published: Sep. 26, 2021
    Downloads:
    Views:
    Abstract: Hodgkin lymphoma (HL), is a B-cell lymphoma. HL is a common hematological malignancy, mostly seen in young and middle-aged people. According to NCCN guidelines, common treatment options include ABVD, BEACOPP, StandfordV, etc. Most HL have a good prognosis and even can be cured. However, some Refractory / Recurrent (R/R) HL, continue to progress dur... Show More
  • Potential Treatment for Multiple Myeloma: Immune Checkpoint Inhibitors

    Jiaxin Wang, Jiaxiong Tan, Yuhong Lu

    Issue: Volume 9, Issue 3, September 2021
    Pages: 59-67
    Received: Sep. 03, 2021
    Accepted: Sep. 17, 2021
    Published: Sep. 26, 2021
    Downloads:
    Views:
    Abstract: Multiple myeloma (MM) is a malignant disease in which monoclonal plasma cells proliferate abnormally. The poor prognosis of MM is always closely related to the immunosuppression of T cells. Restore the immune function of suppressed T cells may reverse the immunodeficiency in the MM microenvironment and improve prognosis. In recent years, immunosupp... Show More